Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population

Ching-Hung Lin, Yoon Sim Yap, Kyung-Hun Lee, Seock-Ah Im, Yoichi Naito, Winnie Yeo, Takayuki Ueno, Ava Kwong, Huiping Li, Shu-Min Huang, Roland Leung, Wonshik Han, Benita Tan, Fu-Chang Hu, Chiun-Sheng Huang, Ann-Lii Cheng, Yen-Shen Lu, Asian Breast Cancer Cooperative Group, Ching-Hung Lin, Yoon Sim Yap, Kyung-Hun Lee, Seock-Ah Im, Yoichi Naito, Winnie Yeo, Takayuki Ueno, Ava Kwong, Huiping Li, Shu-Min Huang, Roland Leung, Wonshik Han, Benita Tan, Fu-Chang Hu, Chiun-Sheng Huang, Ann-Lii Cheng, Yen-Shen Lu, Asian Breast Cancer Cooperative Group

Abstract

Background: The incidence of breast cancer among younger East Asian women has been increasing rapidly over recent decades. This international collaborative study systemically compared the differences in age-specific incidences and pathological characteristics of breast cancer in East Asian women and women of predominantly European ancestry.

Methods: We excerpted analytic data from six national cancer registries (979 675 cases) and eight hospitals (18 008 cases) in East Asian countries and/or regions and, for comparisons, from the US Surveillance, Epidemiology, and End Results program database. Linear regression analyses of age-specific incidences of female breast cancer and logistic regression analyses of age-specific pathological characteristics of breast cancer were performed. All statistical tests were two-sided.

Results: Unlike female colorectal cancer, the age-specific incidences of breast cancer among East Asian women aged 59 years and younger increased disproportionally over recent decades relative to rates in US contemporaries. For years 2010-2014, the estimated age-specific probability of estrogen receptor positivity increased with age in American patients, whereas that of triple-negative breast cancer (TNBC) declined with age. No similar trends were evident in East Asian patients; their probability of estrogen receptor positivity at age 40-49 years was statistically significantly higher (odd ratio [OR] = 1.50, 95% confidence interval [CI] = 1.36 to 1.67, P < .001) and of TNBC was statistically significantly lower (OR = 0.79, 95% CI = 0.71 to 0.88, P < .001), whereas the probability of ER positivity at age 50-59 years was statistically significantly lower (OR = 0.88, 95% CI = 0.828 to 0.95, P < .001). Subgroup analyses of US Surveillance, Epidemiology, and End Results data showed similarly distinct patterns between East Asian American and white American patients.

Conclusions: Contrasting age-specific incidences and pathological characteristics of breast cancer between East Asian and American women, as well as between East Asian Americans and white Americans, suggests racial differences in the biology.

© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Age-specific incidence rates of female breast and colorectal cancers in East Asia and the United States and in SEER Asian Americans and non-Hispanic white Americans. A) The observed age-specific incidence rates of female breast cancer in East Asia (n = 253 840) and the United States (n = 66 230) for years 2011–2014. B) The observed age-specific incidence rates of female colorectal cancer in East Asia (n = 184 055) and the United States (n = 17 688) for years 2011–2014. C) The estimated age-specific incidence rates of female breast cancer in East Asia and the United States for years 2011–2014. D) The estimated age-specific incidence rates of female colorectal cancer in East Asia and the United States for years 2011–2014. The estimated age-specific incidence rates shown in (C) and (D) were based on the fitted multiple linear regression models in Supplementary Table 1 (available online). E) The observed age-specific incidence rates of female breast cancer in SEER Asian Americans (n = 25 665) and non-Hispanic white Americans (n = 683 164) for years 1990–2010. F) The observed age-specific incidence rates of female colorectal cancer in SEER Asian Americans (n = 11 982) and non-Hispanic white Americans (n = 240 286) for years 1990–2010. SEER = Surveillance, Epidemiology, and End Results.
Figure 2.
Figure 2.
Observed age-specific probabilities of ER+ (A), HER2+ (B), TNBC (C), and histological grade III (D) female breast cancer in East Asia and the United States. Age-specific clinicopathological characteristics of female breast cancer were determined based on 18 008 cases from hospital data in East Asian countries and/or regions and 244 819 cases from US SEER data for years 2010–2014. BCH = Beijing Cancer Hospital; ER+ = estrogen receptor positive; HER2+ = human epidermal growth factor receptor 2 positive; KUH = Kyorin University Hospital; NCCHE = National Cancer Center Hospital East; NCCS = National Cancer Centre Singapore; NTUH = National Taiwan University Hospital; PWH = Prince of Wales Hospital; SGH = Singapore General Hospital; SNUH = Seoul National University Hospital; TNBC = triple-negative breast cancer; WCD = West Cluster Database.
Figure 3.
Figure 3.
Conditional effect plots of estimated age-specific probabilities of ER+ (A), HER2+ (B), TNBC (C), and histological grade III (D) female breast cancer in East Asia and the United States for years 2010–2014. The estimated age-specific clinicopathological characteristics of female breast cancer were determined based on the fitted multiple logistic regression models of 18 008 cases in East Asians and 244 819 in Americans (Supplementary Table 2, available online). ER+ = estrogen receptor positive; HER2+ = human epidermal growth factor receptor 2 positive; TNBC = triple-negative breast cancer.
Figure 4.
Figure 4.
Observed age-specific proportions of ER+ (A), HER2+ (B), TNBC (C), and histological grade III (D) female breast cancer in Surveillance, Epidemiology, and End Results program Asian Americans and white Americans for years 2010–2013. The age-specific proportions of ER+, HER2+, TNBC, and histological grade III between 7185 C-J-K Asian Americans and 194 524 white Americans were compared using two-sided pointwise two-sample z tests. The figures show the exact P values when P < .05. C-J-K = Chinese-Japanese-Korean; ER+ = estrogen receptor positive; HER2+ = human epidermal growth factor receptor 2 positive; TNBC = triple-negative breast cancer.

References

    1. Bray F, McCarron P, Parkin DM.. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229–239.
    1. Shin HR, Joubert C, Boniol M, et al. Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control. 2010;21(11):1777–1785.
    1. Youlden DR, Cramb SM, Yip CH, Baade PD.. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11(2):101–115.
    1. Minami Y, Tsubono Y, Nishino Y, Ohuchi N, Shibuya D, Hisamichi S.. The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer. 2004;108(6):901–906.
    1. Shen YC, Chang CJ, Hsu C, Cheng CC, Chiu CF, Cheng AL.. Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1986–1990.
    1. Matsuno RK, Anderson WF, Yamamoto S, et al. Early- and late-onset breast cancer types among women in the United States and Japan. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1437–1442.
    1. Lin CH, Chen YC, Chiang CJ, et al. The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer. 2012;130(11):2629–2637.
    1. Sung H, Rosenberg PS, Chen WQ, et al. Female breast cancer incidence among Asian and Western populations: more similar than expected. J Natl Cancer Inst. 2015;107(7): djv107.
    1. Porter P. “Westernizing” women’s risks? Breast cancer in lower-income countries. N Engl J Med. 2008;358(3):213–216.
    1. Wynder EL, Fujita Y, Harris RE, Hirayama T, Hiyama T.. Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer. 1991;67(3):746–763.
    1. Amadou A, Ferrari P, Muwonge R, et al. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev. 2013;14(8):665–678.
    1. Wada K, Nagata C, Tamakoshi A, et al. Body mass index and breast cancer risk in Japan: a pooled analysis of eight population-based cohort studies. Ann Oncol. 2014;25(2):519–524.
    1. Wu AH, Yu MC, Tseng CC, Pike MC.. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 2008;98(1):9–14.
    1. Hartman M, Suo C, Lim WY, Miao H, Teo YY, Chia KS.. Ability to predict breast cancer in Asian women using a polygenic susceptibility model. Breast Cancer Res Treat. 2011;127(3):805–812.
    1. Kan Z, Ding Y, Kim J, et al. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat Commun. 2018;9(1):1725..
    1. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691.
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
    1. Cancer Information Service NCC, Japan. National estimates of cancer incidence based on cancer registries in Japan (1975. –2013). . Accessed January 12, 2017.
    1. Oh CM, Won YJ, Jung KW, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016;48(2):436–450.
    1. Lee CM, Zheng H, Tan VK, et al. Surgery for early breast cancer in the extremely elderly leads to improved outcomes—An Asian population study. Breast. 2017;36:44–48.
    1. System NHSCROI. Health Promotion Administration, Ministry of Health and Welfare, Taiwan (1979–2013).. Accessed September 2, 2016.
    1. Organization IAfRoCWH. CI5plus, cancer incidence in five continents time trends. . Accessed December 29, 2016.
    1. United States National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence–SEER 9 Regs Research Data. . Accessed November 8, 2016.
    1. United States National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence–SEER 18 Regs Research Data. . Accessed December 16, 2016.
    1. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907–922.
    1. Ogawa YM, Kato Y, Oguma M, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer. 2004;11(3):267–275.
    1. Prat A, Cheang MC, Martin M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31(2):203–209.
    1. United States National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence–SEER 11. . Accessed January 25, 2017.
    1. Lin CH, Liau JY, Lu YS, et al. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer. Epidemiol Biomarkers Prev. 2009;18(6):1807–1814.
    1. Lin CH, Chuang PY, Chiang CJ, et al. Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. Oncologist. 2014;19(6):583–591.
    1. Kurebayashi J, Miyoshi Y, Ishikawa T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015;22(3):235–244.
    1. Ushijima K. Current status of gynecologic cancer in Japan. J Gynecol Oncol. 2009;20(2):67–71.
    1. Lee JY, Kim EY, Jung KW, et al. Trends in gynecologic cancer mortality in East Asian regions. J Gynecol Oncol. 2014;25(3):174–182.
    1. Sans P, Combris P.. World meat consumption patterns: an overview of the last fifty years (1961-2011). Meat Sci. 2015;109:106–111.
    1. MacMahon B, Cole P, Brown JB, et al. Oestrogen profiles of Asian and North American women. Lancet. 1971;2(7730):900–902.
    1. Bernstein L, Yuan JM, Ross RK, et al. Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control. 1990;1(1):51–58.
    1. Key TJ, Chen J, Wang DY, Pike MC, Boreham J.. Sex hormones in women in rural China and in Britain. Br J Cancer. 1990;62(4):631–636.
    1. Goldin BR, Adlercreutz H, Gorbach SL, et al. The relationship between estrogen levels and diets of Caucasian American and Oriental immigrant women. Am J Clin Nutr. 1986;44(6):945–953.
    1. Falk RT, Fears TR, Hoover RN, et al. Does place of birth influence endogenous hormone levels in Asian-American women? Br J Cancer. 2002;87(1):54–60.
    1. Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE.. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2147–2153.
    1. Silva T, Tenreyro S.. Population control policies and fertility convergence. J Econ Perspect. 2017;31(4):205–228.
    1. United Nations, Department of Economic and Social Affairs, Population Division (2017). World Population Prospects: The 2017 Revision, Volume II: Demographic Profiles ST/ESA/SER.A/400. . Accessed December 12, 2017.
    1. Lu YY, Chen ML, Sung FC, Wang PS, Mao IF.. Daily intake of 4-nonylphenol in Taiwanese. Environ Int. 2007;33(7):903–910.
    1. Chen CY, Wen TY, Wang GS, Cheng HW, Lin YH, Lien GW.. Determining estrogenic steroids in Taipei waters and removal in drinking water treatment using high-flow solid-phase extraction and liquid chromatography/tandem mass spectrometry. Sci Total Environ. 2007;378(3):352–365.
    1. Shao B, Hu J, Yang M, An W, Tao S.. Nonylphenol and nonylphenol ethoxylates in river water, drinking water, and fish tissues in the area of Chongqing, China. Arch Environ Contam Toxicol. 2005;48(4):467–473.
    1. Li B, Liu R, Gao H, Tan R, Zeng P, Song Y.. Spatial distribution and ecological risk assessment of phthalic acid esters and phenols in surface sediment from urban rivers in Northeast China. Environ Pollut. 2016;219:409–415.
    1. Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, Higashi Y.. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res. 1998;89(3):254–261.
    1. Gao Y, Huang YB, Liu XO, et al. Tea consumption, alcohol drinking and physical activity associations with breast cancer risk among Chinese females: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2013;14(12):7543–7550.
    1. Dong JY, Qin LQ.. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. 2011;125(2):315–323.
    1. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5): dju055.

Source: PubMed

3
Subskrybuj